Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
This study is being conducted to identify how much and how often pralatrexate, given with
vitamin B12 and folic acid, can be given safely to patients with cutaneous T-cell lymphoma
(CTCL) that has relapsed (returned after responding to previous treatment) or is refractory
(has not responded to previous treatment). It is also being conducted to get information on
whether or not pralatrexate is effective in treating relapsed or refractory CTCL.